Published in Medical Letter on the CDC and FDA, August 3rd, 2008
"Keratinocytes responded with an induction of the canonical NF-kappa B pathway, including activation of I kappa B kinase 2, followed by phosphorylation and degradation of I kappa B alpha and of the transactivating subunit RelA at Ser536. The biphasic NF-kappa B response was strictly dependent on the transactivating subunit RelA, as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.